Security Snapshot

Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) Institutional Ownership

CUSIP: 09203E105

13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

103

Shares (Excl. Options)

37,853,431

Price

$2.43

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
BDTX on Nasdaq
Shares outstanding
58,000,000
Price per share
$2.13
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
37,853,431
Total reported value
$92,001,922
% of total 13F portfolios
0%
Share change
-1,059,083
Value change
-$6,001,452
Number of holders
103
Price from insider filings
$2.13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • BDTX - Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 09203E105.
  • 103 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 103 to 4 between Q4 2025 and Q1 2026.
  • Reported value moved from $92,001,922 to $424,072.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 103 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 09203E105?
CUSIP 09203E105 identifies BDTX - Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BB BIOTECH AG 4.8% -69% $4,373,675 -$9,254,867 2,733,547 -68% BB Biotech AG 19 Mar 2025
BlackRock, Inc. 4.5% $4,037,634 2,523,521 BlackRock, Inc. 31 Mar 2025
Vestal Point Capital, LP 1.5% $2,166,300 870,000 Vestal Point Capital, LP 31 Dec 2025

As of 31 Dec 2025, 103 institutional investors reported holding 37,853,431 shares of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX). This represents 65% of the company’s total 58,000,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 18% 10,606,599 -1.3% 0.02% $25,775,000
NEA Management Company, LLC 7.7% 4,448,757 0% 0.55% $10,810,480
VANGUARD GROUP INC 3.8% 2,188,857 0% 0% $5,318,922
ACADIAN ASSET MANAGEMENT LLC 2.8% 1,630,173 +239% 0.01% $3,956,000
MARSHALL WACE, LLP 1.9% 1,110,088 -15% 0% $2,697,515
Siren, L.L.C. 1.8% 1,046,517 0% 0.08% $2,543,036
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.8% 1,040,468 +16% 0% $2,528,337
JANE STREET GROUP, LLC 1.7% 961,776 +305% 0% $2,337,115
RENAISSANCE TECHNOLOGIES LLC 1.6% 949,735 +58% 0% $2,307,856
BlackRock, Inc. 1.5% 888,260 -14% 0% $2,158,472
Vestal Point Capital, LP 1.5% 870,000 -84% 0.08% $2,114,100
DIMENSIONAL FUND ADVISORS LP 1.5% 857,015 +88% 0% $2,082,832
D. E. Shaw & Co., Inc. 1.1% 655,772 +357% 0% $1,593,526
Connor, Clark & Lunn Investment Management Ltd. 1.1% 654,699 +397% 0% $1,590,919
AWM Investment Company, Inc. 1.1% 625,000 +4.2% 0.15% $1,518,750
FMR LLC 0.93% 541,154 +19% 0% $1,315,005
GEODE CAPITAL MANAGEMENT, LLC 0.87% 505,780 +1.1% 0% $1,229,422
NORTHERN TRUST CORP 0.82% 472,702 -3.1% 0% $1,148,666
CITADEL ADVISORS LLC 0.73% 425,459 0% $1,033,865
WINTON GROUP Ltd 0.73% 421,280 0.04% $1,023,710
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.61% 354,454 +149% 0% $861,323
MACKENZIE FINANCIAL CORP 0.61% 352,454 0% $875,884
GOLDMAN SACHS GROUP INC 0.56% 325,327 -28% 0% $790,545
GLOBEFLEX CAPITAL L P 0.53% 305,276 0% 0.11% $741,821
MILLENNIUM MANAGEMENT LLC 0.51% 296,556 -65% 0% $720,631

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 199,095 $424,072 -$172,910 $2.13 4
2025 Q4 37,853,431 $92,001,922 -$6,001,452 $2.43 103
2025 Q3 38,780,810 $146,973,938 +$5,639,493 $3.79 89
2025 Q2 38,616,493 $95,766,554 -$4,378,949 $2.48 92
2025 Q1 40,656,241 $63,017,852 -$11,756,469 $1.55 83
2024 Q4 47,903,925 $102,516,125 -$13,785,684 $2.14 85
2024 Q3 48,717,118 $211,892,256 +$1,570,817 $4.35 95
2024 Q2 46,760,739 $217,913,327 +$31,657,196 $4.66 88
2024 Q1 39,430,252 $199,910,697 +$10,671,909 $5.07 86
2023 Q4 38,119,952 $107,120,051 +$4,413,540 $2.81 73
2023 Q3 37,180,210 $106,709,201 -$21,943,325 $2.87 71
2023 Q2 41,421,828 $209,176,335 +$105,453,106 $5.05 72
2023 Q1 21,491,972 $40,617,428 +$846,555 $1.89 47
2022 Q4 21,053,167 $37,894,305 -$721,593 $1.80 56
2022 Q3 21,487,475 $36,340,473 -$284,945 $1.69 57
2022 Q2 21,498,645 $52,895,689 -$3,549,739 $2.46 56
2022 Q1 22,887,182 $64,088,307 -$2,429,770 $2.77 69
2021 Q4 23,198,177 $123,630,624 -$12,989,218 $5.33 83
2021 Q3 24,374,413 $206,301,397 -$11,175,534 $8.46 89
2021 Q2 25,397,669 $309,589,838 -$81,437,251 $12.19 97
2021 Q1 29,083,953 $705,520,847 -$7,557,586 $24.26 109
2020 Q4 28,616,097 $917,170,806 +$140,401,559 $32.05 109
2020 Q3 23,764,080 $718,480,421 +$753,590 $30.23 88
2020 Q2 22,835,597 $959,367,654 +$39,864,306 $42.16 79
2020 Q1 22,285,008 $555,219,061 +$555,219,061 $24.95 65